Trial Profile
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary)
- Indications Benign tumours
- Focus Therapeutic Use
- 17 Jan 2020 Status changed from active, no longer recruiting to completed.
- 03 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Jul 2017 Status changed from not yet recruiting to recruiting.